Global Cardiovascular Stent Market Size By Type (Drug Eluting Stents, Bioresorbable Stents), By Application (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Cardiovascular Stent Market was valued at USD 10.4 billion in 2023 and is projected to reach USD 18.6 billion by 2031, expanding at a CAGR of 7.3% during the forecast period (2023–2031). Cardiovascular stents are essential medical devices used to treat narrowed or blocked arteries, primarily caused by coronary artery disease. Rising incidences of cardiovascular disorders, increasing preference for minimally invasive surgeries, and advancements in stent technologies are significantly driving market growth.

Drivers

1. Rising Prevalence of Cardiovascular Diseases (CVDs):

Globally, CVDs remain the leading cause of mortality, increasing the need for effective treatment options like stents. An aging population and lifestyle-related risk factors such as obesity, smoking, and hypertension further amplify demand.

2. Growing Demand for Minimally Invasive Procedures:

Minimally invasive angioplasty procedures, which involve the use of stents, are gaining popularity due to shorter recovery times, reduced hospital stays, and lower surgical risks.

3. Technological Advancements in Stents:

Innovations such as drug-eluting stents (DES), bioresorbable stents, and covered stents enhance efficacy, biocompatibility, and patient outcomes, further propelling market growth.

Restraints

1. High Cost of Procedures and Devices:

The cost associated with advanced stent systems and angioplasty procedures remains a major barrier in developing regions with limited reimbursement frameworks.

2. Risk of Post-Operative Complications:

Despite technological improvements, complications such as in-stent restenosis, thrombosis, or allergic reactions to stent coatings remain concerns, limiting adoption.

Opportunity

1. Untapped Markets in Emerging Economies:

Countries in Asia-Pacific and Latin America offer substantial growth potential due to increasing healthcare spending, awareness of cardiac care, and improving medical infrastructure.

2. Expansion of Outpatient Cardiac Intervention Centers:

The shift toward outpatient cardiac care, supported by portable diagnostic and interventional tools, is creating demand for advanced and cost-effective stent solutions.

Market by System Type Insights

Based on system type, Drug-Eluting Stents (DES) accounted for the largest market share in 2023. Their effectiveness in reducing restenosis has made them the preferred choice for interventional cardiologists. Meanwhile, Bioresorbable Vascular Scaffolds (BVS) are emerging as a promising segment due to their potential to restore natural vascular function after degradation.

Market by End-use Insights

In 2023, Hospitals represented the largest end-use segment due to the availability of skilled personnel, advanced facilities, and high patient inflow. However, Ambulatory Surgical Centers (ASCs) are anticipated to experience the fastest growth owing to cost efficiency and increasing preference for outpatient procedures.

Market by Regional Insights

North America led the global market in 2023, driven by high adoption rates of advanced technologies, favorable reimbursement policies, and the high prevalence of CVDs. However, Asia-Pacific is projected to witness the highest growth, supported by rising healthcare investments, aging demographics, and a surge in lifestyle-related diseases.

Competitive Scenario

Key players in the global cardiovascular stent market include:

Boston Scientific Corporation

Abbott Laboratories

Medtronic plc

Biotronik SE & Co. KG

Terumo Corporation

MicroPort Scientific Corporation

B. Braun Melsungen AG

Cook Medical

Meril Life Sciences

Elixir Medical Corporation

These companies are actively engaged in R&D, product launches, and strategic alliances to enhance their global footprint. For instance:

In 2024, Medtronic launched its next-generation drug-eluting stent with enhanced flexibility and deliverability features.

Abbott gained FDA approval in 2023 for a new DES platform that reduces late stent thrombosis.

In 2025, Boston Scientific acquired a stent-focused startup to expand its bioresorbable stent portfolio.

Scope of Work – Global Cardiovascular Stent Market

Key Market Developments

2023: Abbott Laboratories received CE Mark for its latest bioresorbable scaffold system, enhancing its European market presence.

2024: Terumo Corporation partnered with a major healthcare provider in India to expand access to its advanced DES products.

2025: MicroPort launched an innovative stent platform combining AI-guided placement and drug-elution technology, gaining rapid market traction in China and Southeast Asia.

FAQs

1. What is the current market size of the Global Cardiovascular Stent Market?

The market was valued at USD 10.4 billion in 2023.

2. What is the major growth driver of the Global Cardiovascular Stent Market?

The rising prevalence of cardiovascular diseases and advancements in stent technologies are the primary growth drivers.

3. Which is the largest region during the forecast period in the Global Cardiovascular Stent Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4. Which segment accounted for the largest market share in the Global Cardiovascular Stent Market?

Drug-Eluting Stents (DES) dominated the market based on system type in 2023.

5. Who are the key market players in the Global Cardiovascular Stent Market?

Major players include Boston Scientific, Abbott, Medtronic, Biotronik, Terumo, and others.